A comprehensive view of AIDS/HIV-Positive. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Gilead resubmits application to FDA for approval of long-acting injectable HIV drug lenacapavir after FDA refused authorization in February due to drug’s compatibility with borosilicate glass vial; Gilead now using aluminosilicate glass vial for drug
Published: June 29, 2022 by SeeNews Pharmaceuticals
FDA lifts clinical hold on Gilead’s injectable lenacapavir HIV treatment, pre-exposure prophylaxis as Gilead changes borosilicate glass vials to aluminosilicate glass vials; hold was from concerns about drug’s compatibility with borosilicate vials
Published: May 18, 2022 by Zack's Commentary
FDA approves Hologic’s Aptima CMV Quant assay for use with Hologic’s automated Panther system for solid organ, stem cell transplant patients; test is firm's first post-transplant pathogen detection test in US, joins tests for HIV-1, hepatitis C and B
Published: May 12, 2022 by Business Wire
J&J’s Janssen unit stops development of HPV, hepatitis B vaccines with Bavarian Nordic but keeps Ebola and HIV vaccine programs; J&J to focus on hepatitis B treatments currently under development, including two combination therapies in Phase 2 studies
Published: May 11, 2022 by FierceBiotech
Commentary: mRNA technology used by Pfizer, Moderna for COVID vaccines could end up unlocking much more for future of health care; numerous mRNA vaccine candidates are being researched, undergoing clinical trials for treating cancer, HIV, flu, ebola, more
Published: May 09, 2022 by Bay City Times

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count